Educational content on VJHemOnc is intended for healthcare professionals only. By visiting this website and accessing this information you confirm that you are a healthcare professional.

Share this video  

ASH 2018 | Venetoclax for treating CLL outside the clinical trial setting

Venetoclax, a BCL2 inhibitor, is approved for the treatment of relapsed/refractory chronic lymphocytic leukemia (CLL). Here, Lindsey Roeker, MD, of the Memorial Sloan Kettering Cancer Center, New York City, NY, discusses a study aiming to understand rates of select adverse events including cytopenia, infections, and clinical tumor lysis syndrome (TLS) in CLL patients treated with venetoclax in both community and academic settings. Speaking at the American Society of Hematology (ASH) 2018 Annual Meeting and Exposition in San Diego, CA, Dr Roeker discusses the tolerability, with adverse effects rates like those reported in clinical trials, and states that the dose reduction and interruptions did not appear to impact PFS.